ABSTRACT
INTRODUCTION
Several human tumors overexpress receptors for small regulatory peptides, e.g., somatostatin, bombesin, vasoactive intestinal peptide (VIP), or pituitary adenylate cyclase-activating peptide (PACAP), an observation which has led to a number of clinical applications in the diagnosis and treatment of tumors (1) (2) (3) (4) (5) (6) . VIP is a 28-amino acid neuropeptide, which is widely distributed throughout the brain and periphery, and which structurally belongs to the glucagon-growth hormone releasing factor-secretin superfamily (7) (8) (9) . PACAP was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells (10) . PACAP has recently been shown to exert potent gastrointestinal effects (8, 11) . The 175-amino acid pro-PACAP precursor molecule is tissue-specifically processed to either PACAP38 or PACAP27 (8, 11) .
The biological actions of VIP and PACAP are mediated by a family of three G protein-coupled receptors, which are designated vasoactive intestinal peptide receptor (VPAC) 1 , VPAC 2 , and pituitary adenylate cyclase-activating peptide receptor (PAC) 1 (5, 12, 13) . The PAC 1 receptor exhibits lower affinity for VIP than for PACAP, whereas the VPAC 1 and VPAC 2 receptors exhibit similar affinities for VIP and PACAP (5, (12) (13) (14) (15) . Several observations suggest that VIP/PACAP receptors may be potential targets for tumor imaging and treatment with labeled or unlabeled VIP and PACAP analogs. First, in vitro binding studies have shown that VIP/PACAP receptors are expressed in the great majority of most frequently occurring human tumors, including breast, ovarian, colon, insulinoma, carcinoid, pancreas, glioblastoma, meningioma, pituitary adenoma, and pheochromocytoma (16 -22) . Second, VIP/PACAP receptor-positive intestinal and endocrine tumors can be visualized by in vivo VIP receptor scintigraphy (1, 4, 6, (23) (24) (25) (26) . Third, application of VIP and PACAP analogs modulates tumor growth in animal models (2, 3, (27) (28) (29) (30) (31) (32) (33) .
The expression of VIP/PACAP receptors in human tumors has previously been detected with binding autoradiography or reverse transcription-PCR (16 -22) . However, the diagnostic value of these methods is limited. The determination of the VIP/PACAP receptor status with in vitro autoradiography in routine tumor diagnostic is costly and time-consuming. Given the limited number of selective ligands, it is also difficult to differentiate between individual VIP/PACAP receptor subtypes. Conversely, with reverse transcription-PCR, it is possible to discriminate between VIP/PACAP receptor subtypes; however, this method is based on total RNA isolation from a fresh tumor sample and therefore would not only detect VIP/PACAP receptor transcripts originating from tumor cells but also from fibrocytes, lymphocytes, or other nonmalignant cells. Progress on this front has been hampered by the lack of specific antibodies for immunohistochemical detection of VIP/PACAP receptor proteins.
In the present study, we have generated and characterized a panel of antibodies directed to the COOH-terminal sequences of VIP/PACAP receptor subtypes VPAC 1 , VPAC 2 , and PAC 1 . We have also developed an immunohistochemical protocol that allows efficient detection of these receptors in formalin-fixed, paraffin-embedded human tissues. The generation of these novel antibodies enabled us to determine the cellular distribution of VIP/PACAP receptor proteins in a variety of human tumors and their tissues of origin.
MATERIALS AND METHODS
Patients, Tumors, and Tissue Preparation. Ninetyeight tumor specimens were retrieved from the archives of the Departments of Pathology and Neuropathology. All of the tissue specimens had been fixed in formalin and embedded in paraffin. The following tumors were investigated: colorectal adenocarcinoma (n ϭ 5); ductal pancreatic adenocarcinoma (n ϭ 5); diffuse type gastric cancer (n ϭ 9); intestinal type gastric cancer (n ϭ 8); hepatocellular carcinomas (n ϭ 10); breast carcinoma (n ϭ 4); ovarian carcinoma (n ϭ 10); prostate cancer (n ϭ 4); thyroid carcinoma (n ϭ 6); carcinoid (n ϭ 15); panreatic insulinoma (n ϭ 8); pituitary adenoma (n ϭ 4); pheochromocytoma (n ϭ 2); glioblastoma (n ϭ 4); and meningioma (n ϭ 4). Several of the neuroendocrine tumors contained adjacent normal tissue, which was also analyzed. In addition, several fresh tumor specimens were immediately frozen in liquid N 2 and stored at Ϫ70°C until Western blot analysis. The following tumors were investigated: colorectal carcinoma (n ϭ 6); breast carcinoma (n ϭ 8); ovarian carcinoma (n ϭ 8); thyroid carcinoma (n ϭ 4); pituitary adenoma (n ϭ 4); glioblastoma (n ϭ 8); and meningioma (n ϭ 4).
Generation and Purification of Antipeptide Antibodies. Polyclonal antisera were generated against the COOH-terminal tails of the VIP/PACAP receptor subtypes VPAC 1 , VPAC 2 , and PAC 1 . The identity of the peptides is given in Table 1 . Peptides were synthesized, purified, and coupled to keyhole limpet hemocyanin as described previously. The conjugates were mixed 1:1 with Freund's adjuvant and injected into groups of three rabbits each; 9019 to 9021 for VPAC 1 , 9022 to 9024 for VPAC 2 , and 9025 to 9027 for PAC 1 antisera production. Animals were given injections at 4-week intervals, and serum was obtained 2 weeks after immunizations beginning with the second injection. The specificity of the antisera as well as possible cross-reactivity with other VIP/PACAP receptor subtypes was initially tested with immuno-dot blot analysis as described previously (34, 35) . For subsequent analysis, antibodies were affinity purified against their immunizing peptides with the SulfoLink coupling gel according to the manufacturer's instructions (Pierce, Rockford, IL).
Immunocytochemistry. Plasmids encoding VPAC 1 or VPAC 2 and Chinese hamster ovary (CHO) cells stably expressing PAC 1 were kindly provided by Dr. M. Waelbroeck (Brussels, Belgium). Human embryonic kidney 293 (HEK-293) cells were stably transfected with either VPAC 1 or VPAC 2 . Cells were grown on coverslips overnight and either not exposed or exposed to 1 mol/L VIP or 1 mol/L PACAP27 (Bachem, Weil am Rhein, Germany). Cells were then fixed and incubated with 1 g/mL anti-VPAC 1 (9020), anti-VPAC 2 (9023), or anti-PAC 1 (9027) antibodies followed by cyanin 3.18-conjugated secondary antibodies (Amersham, Braunschweig, Germany). Specimens were mounted and examined with a Leica TCS-NT laser scanning confocal microscope as described previously (34, 36, 37) .
Western Blot Analysis. Membranes were prepared from stably transfected HEK-293 or CHO cells as well as fresh tumor specimens. Cells and tissues were lysed in homogenization buffer [5 mmol/L EDTA, 3 mmol/L EGTA, 250 mmol/L sucrose, and 10 mmol/L Tris-HCl (pH 7.6) containing 1 mmol/L phenylmethylsulfonylfluoride, 1 mol/L pepstatin, 10 g/mL leupeptin, and 2 g/mL aprotinin], and membranes were pelleted at 20,000 ϫ g for 30 minutes at 4°C. Membranes were then dissolved in lysis buffer [150 mmol/L NaCl, 5 mmol/L EDTA, 3 mmol/L EGTA, and 20 mmol/L HEPES (pH 7.4) containing 4 mg/mL dodecyl-␤-maltoside and proteinase inhibitors as describe above] and incubated with 150 L wheat germ lectin agarose beads (Amersham) for 90 minutes at 4°C. Beads were washed five times in lysis buffer, and adsorbed glycoproteins were eluted with SDS-sample buffer for 20 minutes at 60°C. When indicated, adsorbed glycoproteins were subjected to enzymatic deglycosylation with peptide N-glycosidase F (PNGase F) according to the manufacturer's protocol (New England BioLabs, Beverly, MA). Samples were then subjected to 8% SDS polyacrylamide gel electrophoresis and immunoblotted onto nitrocellulose. Blots were incubated with 1 g/mL anti-VPAC 1 (9020), anti-VPAC 2 (9023), or anti-PAC 1 (9027) antibodies followed by peroxidase-conjugated secondary antibodies and enhanced chemiluminescence detection (Amersham). For adsorption controls, antisera were preincubated with 10 g/mL of their cognate peptides for 2 hours at room temperature.
Immunohistochemistry. Seven-m paraffin sections were cut and floated onto positively charged slides and immunohistochemically stained as described previously (34, 38, 39) . Briefly, sections were dewaxed, microwaved in 10 mmol/L citric acid (pH 6.0) for 20 minutes at 600 W, and subsequently incubated with 2 g/mL anti-VPAC 1 (9020), anti-VPAC 2 (9023), or anti-PAC 1 (9027) antibodies overnight at 4°C. Staining of primary antibody was detected with biotinylated goat antirabbit IgG or biotinylated goat antimouse IgG followed by an incubation with avidin-biotinylated peroxidase solution. Tissue was then rinsed and stained with 3,3Ј-diaminobenzidineglucose oxidase for 15 minutes. Cell nuclei were lightly counter- 
RESULTS
Characterization of VIP/PACAP Receptor Antibodies. Specificity of the antisera was monitored with Western blot analysis. When membrane preparations from stable transfected cells were electrophoretically separated and blotted onto nitrocellulose, the antisera 9020 (anti-VPAC 1 ), 9023 (anti-VPAC 2 ), and 9027 (anti-PAC 1 ) revealed broad bands in cells transfected with their cognate VIP/PACAP receptor subtype (Fig. 1) . In HEK-293 cells stably expressing VPAC 1 , the anti-VPAC 1 antibody (9020) detected a broad band migrating at M r 55,000 to 70,000 (Fig. 1A) . In HEK-293 cells stably expressing VPAC 2 , the anti-VPAC 2 antibody (9023) detected a single broad band migrating at M r 50,000 to 65,000 (Fig. 1B) . In CHO cells stably expressing PAC 1 , the anti-PAC 1 antibody detected a broad band migrating at M r 40,000 to 60,000 (Fig. 1C) . Enzymatic deglycosylation with PNGase F resulted in shift of molecular size and appearance of all three VIP/PACAP receptor proteins (Fig. 1 ). Antisera were additionally characterized with immunofluorescent staining of transfected cells. When HEK-293 cells stably expressing VPAC 1 or VPAC 2 and CHO cells stably expressing PAC 1 were stained with anti-VPAC 1 (9020), anti-VPAC 2 (9023), or anti-PAC 1 (9027) antibodies, prominent immunofluorescence localized at the level of the plasma membrane was detected (Fig. 2, A, C , and E). After incubation with VIP or PACAP27, VPAC 1 -, VPAC 2 -, and PAC 1 -immunoreactivity was translocated from the plasma membrane into the cytosol, indicating that all of the VIP/PACAP receptor subtypes were rapidly endocytosed in an agonist-dependent manner (Fig. 2, B, D, and  F) . Whereas VPAC 1 and VPAC 2 were internalized in response to both VIP and PACAP27, PAC 1 was selectively internalized in response to PACAP27 (data not shown). Next, the antisera were tested for possible cross-reactivity with other proteins Fig. 1 Western blot analysis of the specificity of anti-VPAC 1 , anti-VPAC 2 , and anti-PAC 1 antibodies. Membrane preparations from HEK-293 stably transfected to express either VPAC 1 or VPAC 2 and CHO cells were stably transfected to express PAC 1 were separated on 8% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. When indicated receptor proteins were subjected to enzymatic deglycosylation with PNGase F (Ϯ). Membranes were then incubated with affinity-purified anti-VPAC 1 (9020; A), anti-VPAC 2 (9023; B), or anti-PAC 1 (9027; C) antibodies at a concentration of 1 g/mL. Blots were developed with enhanced chemiluminescence. Two additional experiments gave similar results. Ordinate, migration of protein molecular weight markers (M r ϫ 10 Ϫ3 ). present in human tissues. When membrane preparations from a variety of human tumors were electrophoretically separated and blotted onto nitrocellulose, the antisera revealed broad receptorlike bands with molecular weights similar to that observed for recombinant VIP/PACAP receptors, e.g., the anti-VPAC 1 antibody (9020) detected a broad band migrating at M r 55,000 to 75,000 in an ovarian carcinoma (Fig. 3 A) , the anti-VPAC 2 antibody (9023) detected a broad band migrating at M r 60,000 to 75,000 in a breast carcinoma (Fig. 3B) , and the anti-PAC 1 antibody (9027) detected a broad band migrating at M r 50,000 to 65,000 in a glioblastoma (Fig. 3C) . Immunoreactive bands for each antiserum were completely abolished by preabsorbtion with 10 g/mL of their immunizing peptides (Fig. 3, A-C) . VIP/PACAP Receptor Immunohistochemical Staining in Normal and Neoplastic Human Tissues. The anti-VPAC 1 (9020), anti-VPAC 2 (9023), and anti-PAC 1 (9027) antibodies were subjected to immunohistochemical staining of a variety of human tissues. Initial experiments showed that heat-induced epitope retrieval is required for efficient immunohistochemical staining of paraffin-embedded tissue (data not shown). Many neuroendocrine tumors contained adjacent noncancerous tissue, which enabled us to analyze the distribution of VIP/PACAP receptors in several parts of the normal gastrointestinal tract. Prominent localizations of VPAC 1 , VPAC 2 , and PAC 1 receptors in the small intestine are shown in Fig. 4 . VPAC 1 receptor immunoreactivity was abundant in the mucosa (Fig. 4A) . The highest densities of immunoreactive VPAC 1 receptors were observed in epithelial cells located in the basal portion of the crypts (Fig. 4A) . In epithelial cells, VPAC 1 receptor immunoreactivity was predominantly confined to the plasma membrane (Fig. 4B) . In contrast, VPAC 2 receptor immunoreactivity was not seen in epithelial cells but selectively localized to neuroendocrine cells (Fig. 4C) . In neuroendocrine cells, immunoreactive VPAC 2 receptors were distributed throughout the cytosol (Fig.  4C) . VPAC 2 receptor immunoreactivity was also seen in smooth muscle of the gastrointestinal tract and blood vessels (Fig. 4D) . VPAC 1 receptor immunoreactivity was observed in myenteric neurons as well as in fibers distributed to the muscle layer (Fig.  4E) . In addition, VPAC 1 receptor immunoreactivity was abundant in neurons of the mucosal plexus (data not shown). PAC 1 receptor immunoreactivity was also observed in many neurons of the myenteric plexus (Fig. 4F) . The anti-VPAC 1 (9020), anti-VPAC 2 (9023), and anti-PAC 1 (9027) antibodies were then subjected to immunohistochemical staining of 98 human tumors. All three antibodies yielded prominent staining predominantly localized to the plasma membrane of the tumor cells (Fig. 5) . The staining intensity for each antibody varied greatly between individual tumors giving consistently different samplespecific patterns of VIP/PACAP receptor subtype expression under otherwise identical conditions. Immunostaining for each antiserum was completely abolished by preadsorbtion with 10 g/mL of the immunizing peptides (Fig. 5) . Table 2 summarizes the incidence of VPAC 1 , VPAC 2 , and PAC 1 receptors in a series of human tumors, including some of the most frequently occurring carcinomas. The VPAC 1 , VPAC 2 , or PAC 1 receptors were found in every tumor except thyroid cancer, which was completely devoid of any of the VIP/PACAP receptors ( Table 2 ). The VPAC 1 receptor was found most commonly in cancers of the breast, pancreas, and prostate, as well as in pituitary adenomas. The VPAC 2 receptor was commonly expressed in meningiomas and less frequently in carcinoids, insulinomas, gastric cancers, and breast cancers. The VPAC 2 receptor was also found in a single pheochromocytoma. The PAC 1 receptor was most commonly expressed by neuroendocrine tumors, meningiomas, and breast cancer, and was rarely found in cancers of the stomach, liver, colorectum, thyroid, or prostate. A uniform highly abundant expression of all of the VIP/PACAP receptor subtypes was only evident in glioblastomas ( Table 2) . VPAC 1 , VPAC 2 , and PAC 1 were also present at the plasma membrane of neuronal cell bodies and processes adjacent to the glioblastomas (data not shown).
DISCUSSION
In an effort to study the pattern of VIP/PACAP receptor protein expression in normal and neoplastic human tissues, we generated antibodies that exert selective specificity for VPAC 1 , VPAC 2 , and PAC 1 receptors. We show that the cytoplasmic tails of these receptors can serve as an epitope for the generation of antisera that effectively stain formalin-fixed, paraffin-embedded human tissues. Several lines of evidence indicate that these antibodies specifically detect their targeted VIP/PACAP receptor and do not cross-react. First, in Western blots of membranes from receptor-transfected cells, the anti-VPAC 1 , anti-VPAC 2 , and anti-PAC 1 antibodies detected broad bands migrating at M r 50,000 to 70,000. Second, anti-VPAC 1 , anti-VPAC 2 , and anti-PAC 1 antibodies revealed prominent cell surface staining of VIP/PACAP receptor-transfected cells. This immunostaining translocated from the cell surface into the cytosol after agonist exposure, indicating rapid endocytosis of all three VIP/PACAP receptor subtypes. Third, in Western blots of membranes from receptor-expressing tumors, the anti-VPAC 1 , anti-VPAC 2 , and anti-PAC 1 antibodies detected single bands migrating at the appropriate molecular weight. Fourth, tissue immunostaining of all three antisera was completely abolished by preadsorbtion with homologous but not heterologous peptides. Finally, it should be noted that two of three VPAC 1 , three of three VPAC 2 , and two of three PAC 1 antisera gave similar results.
The availability of subtype-specific VIP/PACAP receptor antibodies will facilitate additional basic morphologic investigation of VPAC 1 , VPAC 2 , and PAC 1 receptor expression in human tumors and normal human tissues. The immunohistochemical VIP/PACAP receptor evaluation offers several major advantages. This new method can analyze VIP/PACAP receptors in routinely processed archival paraffin-embedded material of any diagnostic pathology center. It requires only an immunopathological laboratory to perform the test, which can be carried out without costly and time-consuming receptor autoradiography. The immunohistochemical evaluation of the complete VIP/PACAP receptor status of a given tumor specimen can be accomplished in Ͻ24 hours. Although one could expect the immunohistochemical VIP/PACAP receptor determination to be less sensitive than receptor autoradiography with 125 I-labeled VIP, the sensitivity of the anti-VPAC 1 (9020), anti-VPAC 2 (9023), and anti-PAC 1 (9027) antibodies generated and characterized in this study was sufficiently high enough to detect these receptors in known human VIP/PACAP target tissues, i.e., detection of VPAC 1 in gastrointestinal mucosa and VPAC 2 in smooth muscle of the gastrointestinal tract. In addition, the immunohistochemical VIP/PACAP receptor determination provided a better histologic quality and cellular resolution compared with receptor autoradiography. Thus, previously unappreciated cellular localizations of VIP/PACAP receptors were uncovered, i.e., presence of VPAC 1 in myenteric nerve fibers and VPAC 2 in neuroendocrine cells.
Although VPAC 1 , VPAC 2 , and PAC 1 were all highly abundant throughout the gastrointestinal tract, the various VIP/ PACAP receptor subtypes exhibited complementary expression patterns. Previous studies have shown that VIP immunoreactivity is present in neuroendocrine cells as well as in submucous and myenteric ganglia of the human gut (40 -42) . VIP immunoreactivity is also present in mucosal and myenteric nerve fibers as well as in nerve fibers innervating blood vessels (40 -42) . PACAP immunoreactivity exhibits a nearly identical distribution (40 -42) . In fact, dual immunofluorescence studies revealed a high degree of coexistence of the two peptides (40 -42) . Thus, the present findings suggest distinct roles of individual VIP/PACAP receptor subtypes in gastrointestinal physiology. VPAC 1 in the mucosa is targeted by VIP and PACAP released from mucosal nerve fibers and neuroendocrine cells and is possibly involved in the regulation of secretion. VPAC 2 in the smooth muscle of the gastrointestinal wall is targeted by VIP and PACAP released from myenteric nerve fibers and is probably involved in the regulation of motor activity. Conversely, VPAC 2 in the smooth muscles of blood vessels may regulate gastrointestinal blood flow. VPAC 1 in myenteric nerve fibers is likely to function as autoreceptor, regulating the release of VIP and PACAP. VPAC 2 in neuroendocrine cells may also function as autoreceptor, which may explain the high levels of internalized receptors detected in these (2, 3, (27) (28) (29) (30) (31) (32) (33) . Whereas growth-promoting activities have been reported for VIP, growth-inhibiting properties have been found for VIP antagonists in various tumor models (2, 3, (27) (28) (29) (30) (31) (32) (33) . VIP/PACAP receptors are detectable in the great majority of most frequently occurring human tumors, including breast, ovarian, colon, insulinoma, carcinoid, pancreas, glioblastoma, meningioma, pituitary adenoma, and pheochromocytoma. It is therefore very tempting to suggest the use of growth-inhibiting VIP/PACAP analogs for the treatment of human tumors (16 -22) . Moreover, a number of clinical and preclinical studies suggest that VIP/PACAP receptors may be promising molecular targets for tumor imaging and targeted radiotherapy (1, 4, 6, (23) (24) (25) (26) . However, previous and present evidence indicates a highly abundant expression of VIP/PACAP receptors in normal human target tissues. Thus, for potential clinical application of VIP/PACAP analogs, the ratio of receptor expression in neoplastic versus normal tissues should be determined with subtype-specific VIP/PACAP receptor antibodies.
In conclusion, we have generated and extensively characterized anti-VPAC 1 , anti-VPAC 2 , and anti-PAC 1 antibodies. Using these antibodies, we provide the first demonstration of all of the VIP/PACAP receptor subtypes in human formalin-fixed, paraffin-embedded tissues. It is now possible to determine the exact cellular and subcellular sites of VIP/PACAP receptor protein expression in normal human tissues, which is needed for a better understanding of VIP/PACAP actions in physiologic target tissues. The rapid immunocytochemical VIP/PACAP receptor visualization may also be helpful to identify those tumors with a sufficient receptor overexpression for diagnostic or therapeutic intervention.
